Revance Announces U.S. FDA Acceptance of Supplemental Biolog

Revance Announces U.S. FDA Acceptance of Supplemental Biologics License Application (sBLA) for DAXXIFY® (DaxibotulinumtoxinA-lanm) for Injection for the Treatment of Cervical Dystonia

Revance Announces U.S. FDA Acceptance of Supplemental Biologics License Application (sBLA) for DAXXIFY® (DaxibotulinumtoxinA-lanm) for Injection for the Treatment of Cervical Dystonia
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

United States , California , Tennessee , Irvine , Markj Foley , Laurence Watts , Jessica Serra , Sara Fahy , Peter Mcallister , Allergan Inc , Linkedin , Nasdaq , Revance Therapeutics Inc , Hint Inc , Dystonia Medical Research Foundation , Drug Administration , Peptide Exchange Technology , Evolus Inc , Exchange Commission , Gilmartin Group , Ipsen Biopharmaceuticals Ltd , Merz Pharmaceuticals Gmb , Securities Exchange , Viatris Inc , Decision Resources Group Aesthetics Injectables Market Insights , Drug User Fee Act , Biologics License Application , Prescription Drug User Fee Act , Chief Executive , Boxed Warning , Distant Spread , Prescribing Information , Relational Commerce , Revance Therapeutics , Hyaluronic Acid , Private Securities Litigation Reform Act , Securities Act , Securities Exchange Act , Medical Research , Plast Reconstr , Merz Pharmaceuticals Gmbh , Ipsen Biopharmaceuticals ,